Prognostic value of PR in Luminal B HER2 (-) lymph-node-negative breast cancer
10.3760/cma.j.issn.1674-6090.2017.02.004
- VernacularTitle:PR在Luminal B HER2(-)腋窝淋巴结阴性乳腺癌中的预后价值
- Author:
Ying LIU
;
Yan MAO
;
Weihong CAO
;
Haibo WANG
;
Yunjiao WANG
- Keywords:
Breast cancer;
Progesterone receptor;
Luminal B;
HER2
- From:
Chinese Journal of Endocrine Surgery
2017;11(2):101-106
- CountryChina
- Language:Chinese
-
Abstract:
Objective To assess the prognostic value of progesterone receptor (PR) in Luminal B HER2(-) lymph-node-negative breast cancer.Methods The clinical data of 196 Luminal B HER2 (-) lymph-node-negative breast cancer patients were collected in this study.The correlation between PR and clinicopathological factors and its influence on prognosis was analyzed.Results Among 196 patients with Luminal B HER2 (-) lymph-node-negative breast cancer,14.8％(29/196)were PR-negative and 85.2％(167/196)were PR-positive (HR=3.25,95.0％ CI:0.73-1.45,P=0.123).PR negativity indicated postmenopausal status (P=0.029) and high tumor grade (P=0.001).Mter a median follow-up of 60 months,9.7％(19/196) of the patients had relapses and 4.1％(8/196) died of breast cancer.The 5-year disease-free survival(DFS) was 75.9％ in PR-negative group and 92.8％ in PR-positive group (Log-rank P=0.001).The 5-year overall survival (OS) was 89.7％ in PR-negative group and 97.0％ in PR-positive group (Log-rank P=0.023).In multivariate analysis,PR negativity was significantly associated with a poor 5-year DFS (HR=2.85,95.0％ CI:1.05-7.72,P=0.039)but not with 5-year OS (HR=1.78,95.0％ CI:0.34-9.35,P=0.495).Conclusion In this study,PR is a prognostic factor for relapse in Luminal B HER (-) lymph-node-negative breast cancer.
